Separate validation value from market value

A small indication can be strategically valuable if it produces a fast, objective signal that validates mechanism or platform.

Score information value

Compare mechanistic fit, biomarker enrichment, endpoint speed, patient availability, competitive intensity, regulatory path and commercial option value.

Sequence instead of declaring a permanent winner

The right first indication can create evidence that changes the ranking of the next indications.

Questions people actually ask

FAQ

Should TAM drive indication choice?

TAM matters, but before human proof it should not automatically dominate information value.

Can multiple indications run in parallel?

Yes, when the extra capital preserves valuable optionality and does not weaken execution.

Related

Cost-to-Truth: A Better Way to Think About Clinical Development SpendCost-to-Truth asks how much time and money are required to obtain the next credible answer that changes a management decision. Biotech Licensing Diligence: What to Check Before Spending Months on a DealResolve whether the asset is actionable before building an elaborate valuation. What Should a First-in-Human Trial Prove Besides Safety?A first-in-human study can be designed to create strategic evidence, not merely complete a conventional Phase 1 checklist.

Do the useful thing now

Use the tool instead of guessing.

See an indication-prioritization example